Evidence map›Paper›PMID 39825567›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Enhanced restoration of visual code after targeting ON bipolar cells compared with retinal ganglion cells with optogenetic therapy.

Jessica Rodgers, Steven Hughes, Aghileh S Ebrahimi, Annette E Allen, Riccardo Storchi, Moritz Lindner, Stuart N Peirson, Tudor C Badea, Mark W Hankins, Robert J Lucas

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Optogenetic vision restoration in the face of secondary and tertiary remodeling in the rd1 mouse retina.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  5. Review
  6. Turning ON the inner retinal circuity: An exciting new approach to optogenetic therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica RodgersFaculty of Biology, Medicine & Health, University of Manchester, Manchester M13 9PT, UK.
Steven HughesNuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
Aghileh S EbrahimiFaculty of Biology, Medicine & Health, University of Manchester, Manchester M13 9PT, UK.
Annette E AllenFaculty of Biology, Medicine & Health, University of Manchester, Manchester M13 9PT, UK.
Riccardo StorchiFaculty of Biology, Medicine & Health, University of Manchester, Manchester M13 9PT, UK.
Moritz LindnerNuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX1 3QU, UK; Institute of Physiology and Pathophysiology, Department of Neurophysiology, Philipps University, 35037 Marburg, Germany; Department of Ophthalmology, University Hospitals of Giessen and Marburg, 35043 Marburg, Germany.
Stuart N PeirsonNuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
Tudor C BadeaNeurogenetics Laboratory/ICDT, Transilvania University of Brasov, 500484 Brasov, Romania; National Brain Research Centre/ICIA, Romanian Academy, 050711 Bucharest, Romania.
Mark W HankinsNuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK. Electronic address: mark.hankins@eye.ox.ac.uk.
Robert J LucasFaculty of Biology, Medicine & Health, University of Manchester, Manchester M13 9PT, UK. Electronic address: robert.lucas@manchester.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optogenetic therapy is a promising vision restoration method where light-sensitive opsins are introduced to the surviving inner retina following photoreceptor degeneration. The cell type targeted for opsin expression will likely influence the quality of restored vision. However, a like-for-like preclinical comparison of visual responses evoked following equivalent opsin expression in the two major targets, ON bipolar (ON BCs) or retinal ganglion cells (RGCs), is absent. We address this deficit by comparing stimulus-response characteristics at single-unit resolution in the retina and dorsal lateral geniculate nucleus of retinally degenerate mice genetically engineered to express the opsin ReaChR in Grm6- or Brn3c-expressing cells (ON BC vs. RGCs, respectively). For both targeting strategies, we find ReaChR-evoked responses have equivalent sensitivity and can encode contrast across different background irradiances. Compared with ON BCs, targeting RGCs decreased response reproducibility and resulted in more stereotyped responses with reduced diversity in response polarity, contrast sensitivity, and temporal frequency tuning. Recording ReaChR-driven responses in visually intact retinas confirmed that RGC-targeted ReaChR expression disrupts visual feature selectivity of individual RGCs. Our data show that, while both approaches restore visual responses with impressive fidelity, ON BC targeting produces a richer visual code closer to that of wild-type mice.

Indexed as

OptogeneticsRetinal Bipolar CellsRetinal DegenerationRetinal Ganglion CellsVision, OcularAnimalsGenetic TherapyMiceMice, TransgenicOpsinsReceptors, Metabotropic Glutamatemetabotropic glutamate receptor 6OpsinsReceptors, Metabotropic Glutamatecell targetingopsinsoptogenetic therapyretinal degenerationvision restoration

Identifiers

PMID39825567
PMCPMC11897768

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.